A randomized trial reported in Translational Psychiatry suggests that esketamine-based, opioid-free anesthesia may deliver a twofold advantage for people undergoing bariatric surgery—reducing both postoperative pain and subsequent mental health symptoms. The study addresses a persistent clinical tension: while opioids can help manage perioperative discomfort, they are also linked to adverse outcomes including heightened pain sensitivity and postoperative mood disturbances.
Researchers enrolled patients scheduled for bariatric procedures and compared an esketamine-based anesthesia approach designed to avoid opioid exposure against conventional opioid-containing strategies. Esketamine, an NMDA-receptor modulator, is known to influence central sensitization pathways that can amplify postoperative pain. By targeting these mechanisms, the trial aimed to improve recovery while limiting opioid-related risks.
Pain outcomes were tracked after surgery using standardized assessments at multiple postoperative timepoints. Investigators report that patients receiving esketamine-based opioid-free anesthesia experienced lower pain burden than those in the comparator group. The pattern supports the hypothesis that NMDA modulation may dampen nociceptive signaling and reduce the trajectory toward persistent or exaggerated pain.
Beyond analgesia, the trial evaluated mental health-related endpoints, including indicators of anxiety or depressive symptoms during recovery. Importantly, the authors emphasize that postoperative psychological well-being is not independent of pain experience; rather, pain and mood can reinforce each other through stress and neurobiological pathways.
The study’s results suggest that improved pain control may partially translate into better mental health outcomes, consistent with a broader neuropsychiatric framework in perioperative care. In this view, attenuating inflammatory and sensory stress responses could help preserve emotional stability during recovery.
Because this was a randomized controlled trial, the findings carry greater causal weight than observational reports. Nevertheless, the authors note that clinical adoption would depend on balancing efficacy with practical considerations such as monitoring requirements for esketamine and institutional protocols for opioid-free regimens.
Overall, the work positions esketamine-based anesthesia as a promising strategy for enhanced recovery after surgery in bariatric patients, potentially addressing both somatic and psychological dimensions of postoperative recovery. If replicated in larger, diverse cohorts, this approach could reshape anesthetic planning for patients at risk of pain-related and mood-related complications.
Subject of Research: Bariatric surgery anesthesia outcomes (postoperative pain and mental health)
Article Title: Dual benefit of esketamine-based opioid-free anesthesia on postoperative pain and mental health outcomes in patients undergoing bariatric surgery: a randomized controlled trial.
Article References: Huang, C., Guan, Z., Wang, S. et al. Dual benefit of esketamine-based opioid-free anesthesia on postoperative pain and mental health outcomes in patients undergoing bariatric surgery: a randomized controlled trial. Translational Psychiatry (2026). https://doi.org/10.1038/s41398-026-04241-w
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41398-026-04241-w
Keywords:
